Outlook Therapeutics IncNASDAQ:OTLK
- LAST PRICE4.9410
- TODAY'S CHANGE (%)0.0110 (0.2231%)
- Bid / Lots4.9300/ 6
- Ask / Lots4.9500/ 1
- Open / Previous Close4.9400 / 4.9300
- Day Range
- 52 Week Range
- Volume332,189
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OTLK |
|---|---|---|
| 09:32 ET | 6962 | 4.985 |
| 09:33 ET | 1967 | 4.945 |
| 09:35 ET | 400 | 4.93 |
| 09:37 ET | 1750 | 4.97 |
| 09:39 ET | 5671 | 5 |
| 09:42 ET | 200 | 5.09 |
| 09:44 ET | 6021 | 4.96 |
| 09:46 ET | 100 | 5 |
| 09:48 ET | 1653 | 5.01 |
| 09:50 ET | 7242 | 5.045 |
| 09:51 ET | 16650 | 5.0212 |
| 09:53 ET | 500 | 5.06 |
| 09:55 ET | 1026 | 5.06 |
| 09:57 ET | 2000 | 5.08 |
| 10:00 ET | 2392 | 5.07 |
| 10:02 ET | 400 | 5.06 |
| 10:04 ET | 100 | 5.06 |
| 10:06 ET | 1067 | 5.05 |
| 10:08 ET | 100 | 5.05 |
| 10:11 ET | 150 | 5.0601 |
| 10:13 ET | 969 | 5.05 |
| 10:15 ET | 781 | 5.05 |
| 10:18 ET | 400 | 5.05 |
| 10:20 ET | 100 | 5.04 |
| 10:22 ET | 900 | 5.02 |
| 10:24 ET | 24101 | 5 |
| 10:26 ET | 5867 | 5 |
| 10:27 ET | 651 | 5.02 |
| 10:29 ET | 700 | 5.03 |
| 10:33 ET | 1241 | 5.049 |
| 10:36 ET | 100 | 5.0318 |
| 10:38 ET | 682 | 5.07 |
| 10:40 ET | 100 | 5.07 |
| 10:42 ET | 4325 | 5.1 |
| 10:44 ET | 200 | 5.1219 |
| 10:47 ET | 580 | 5.12 |
| 10:54 ET | 2109 | 5.13 |
| 10:56 ET | 200 | 5.13 |
| 10:58 ET | 2200 | 5.12 |
| 11:00 ET | 157 | 5.12 |
| 11:03 ET | 6382 | 5.06 |
| 11:05 ET | 2606 | 5.08 |
| 11:07 ET | 560 | 5.0979 |
| 11:09 ET | 1300 | 5.04 |
| 11:12 ET | 600 | 5.0194 |
| 11:14 ET | 400 | 5.015 |
| 11:16 ET | 200 | 5.02 |
| 11:20 ET | 1600 | 5.02 |
| 11:21 ET | 419 | 5.03 |
| 11:23 ET | 100 | 5.02 |
| 11:27 ET | 1419 | 5.0299 |
| 11:30 ET | 100 | 5.03 |
| 11:32 ET | 585 | 5.02 |
| 11:34 ET | 1354 | 5.01 |
| 11:36 ET | 1314 | 5.02 |
| 11:38 ET | 3440 | 5.0101 |
| 11:41 ET | 200 | 5.019 |
| 11:43 ET | 310 | 5.0192 |
| 11:45 ET | 200 | 5.01 |
| 11:48 ET | 14503 | 5.01 |
| 11:50 ET | 100 | 5.01 |
| 11:56 ET | 1500 | 5.02 |
| 12:01 ET | 700 | 5.0131 |
| 12:03 ET | 400 | 5.01 |
| 12:08 ET | 1400 | 5.005 |
| 12:10 ET | 7517 | 5.005 |
| 12:12 ET | 2300 | 5.005 |
| 12:14 ET | 979 | 5.0088 |
| 12:15 ET | 2874 | 5.008599 |
| 12:19 ET | 200 | 5 |
| 12:21 ET | 600 | 5.005 |
| 12:24 ET | 200 | 5 |
| 12:26 ET | 2117 | 5 |
| 12:30 ET | 2080 | 5.01 |
| 12:32 ET | 2400 | 5.01 |
| 12:33 ET | 1000 | 5.015 |
| 12:35 ET | 500 | 5.015 |
| 12:37 ET | 1000 | 5.02 |
| 12:39 ET | 100 | 5.02 |
| 12:42 ET | 14100 | 5.015 |
| 12:44 ET | 500 | 5.015 |
| 12:48 ET | 43757 | 5 |
| 12:51 ET | 700 | 4.98 |
| 12:53 ET | 3878 | 4.96 |
| 12:55 ET | 2200 | 4.958 |
| 12:57 ET | 5590 | 4.94 |
| 01:00 ET | 100 | 4.94 |
| 01:02 ET | 500 | 4.94 |
| 01:04 ET | 1600 | 4.935 |
| 01:06 ET | 5228 | 4.97 |
| 01:08 ET | 1300 | 4.98 |
| 01:09 ET | 1400 | 4.975 |
| 01:11 ET | 600 | 4.96 |
| 01:13 ET | 200 | 4.97 |
| 01:15 ET | 400 | 4.97 |
| 01:18 ET | 517 | 4.97 |
| 01:22 ET | 600 | 4.97 |
| 01:24 ET | 1100 | 4.95 |
| 01:26 ET | 300 | 4.95 |
| 01:27 ET | 3005 | 4.98 |
| 01:31 ET | 3695 | 4.946 |
| 01:33 ET | 1200 | 4.95 |
| 01:36 ET | 1537 | 4.94 |
| 01:38 ET | 3100 | 4.93 |
| 01:40 ET | 100 | 4.93 |
| 01:42 ET | 100 | 4.93 |
| 01:44 ET | 100 | 4.94 |
| 01:45 ET | 2281 | 4.9385 |
| 01:47 ET | 230 | 4.9342 |
| 01:49 ET | 700 | 4.93 |
| 01:54 ET | 900 | 4.92 |
| 01:56 ET | 1375 | 4.93 |
| 01:58 ET | 485 | 4.93 |
| 02:00 ET | 100 | 4.93 |
| 02:05 ET | 1055 | 4.93 |
| 02:09 ET | 200 | 4.93 |
| 02:12 ET | 600 | 4.94 |
| 02:14 ET | 500 | 4.94 |
| 02:16 ET | 2836 | 4.925 |
| 02:18 ET | 100 | 4.92 |
| 02:20 ET | 1600 | 4.92 |
| 02:21 ET | 2200 | 4.92 |
| 02:23 ET | 954 | 4.92 |
| 02:27 ET | 300 | 4.92 |
| 02:30 ET | 500 | 4.92 |
| 02:32 ET | 2094 | 4.93 |
| 02:34 ET | 160 | 4.93 |
| 02:36 ET | 556 | 4.935 |
| 02:38 ET | 700 | 4.93 |
| 02:45 ET | 600 | 4.935 |
| 02:50 ET | 1358 | 4.94 |
| 02:54 ET | 1173 | 4.93 |
| 02:59 ET | 100 | 4.9353 |
| 03:03 ET | 100 | 4.94 |
| 03:06 ET | 200 | 4.94 |
| 03:08 ET | 100 | 4.94 |
| 03:10 ET | 160 | 4.9316 |
| 03:12 ET | 246 | 4.941 |
Nov 6, 2024
Outlook Therapeutics(R) to Present at the Guggenheim Healthcare Innovation Conference, from 8:05AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:05AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Outlook Therapeutics Inc | 119.0M | -0.6x | --- |
Invizyne Technologies Inc | 121.1M | -21.9x | --- |
Alto Neuroscience Inc | 116.2M | -1.8x | --- |
Skye Bioscience Inc | 125.0M | -5.1x | --- |
Pyxis Oncology Inc | 113.0M | -1.7x | --- |
Rani Therapeutics Holdings Inc | 111.5M | -1.9x | --- |
Company Information
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Contact Information
- Headquarters
- 111 S. Wood Avenue, Unit #100ISELIN, NJ, United States 08830
- Phone
- 609-619-3990
- Fax
- ---
Executives
- Independent Executive Chairman of the Board
- Ralph Thurman
- President, Chief Executive Officer, Director
- C. Russell Trenary
- Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
- Lawrence Kenyon
- Senior Vice President - Head of Europe
- Jedd Comiskey
- Senior Vice President - Licensing and M&A
- Joel Prieve
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $119.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 23.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.62 |
EPS | $-8.12 |
Book Value | $-1.11 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
